Supernus Pharmaceuticals
An award-winning biopharmaceutical company with more than 30 years of experience in developing and commercializing products that treat central nervous system (CNS) diseases.
Last updated September 1, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Supernus Pharmaceuticals is an award-winning biopharmaceutical company with more than 30 years of experience in developing and commercializing products that treat central nervous system (CNS) diseases. The company has eight marketed products that impact patients' lives across migraine prevention, epilepsy, Parkinson's disease, and ADHD, with its launch product Qelbree. Supernus has received numerous awards, including Forbes America's Best Small Companies 2021 and Fortune Magazine's 100 Fastest Growing Companies.
History
Supernus Pharmaceuticals is a biopharmaceutical company with more than 30 years of experience in developing and commercializing products that treat central nervous system (CNS) diseases. The company has eight marketed products that impact patients' lives across migraine prevention, epilepsy, Parkinson's disease, and ADHD, with its launch product Qelbree. Supernus has received numerous awards, including Forbes America's Best Small Companies 2021 and Fortune Magazine's 100 Fastest Growing Companies.
Controversies
2021
Supernus sues over Oxtellar XR patents
Supernus Pharmaceuticals filed suit against Riconpharma and Ingenus, alleging patent infringement connected to their joint abbreviated new drug application for generic oxcarbazepine extended-release tablets. The infringement allegations are claims made by Supernus.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/supernus-pharmaceuticals-united-states · Editorial policy · How profiles are compiled